- Home
- SGLY vs PALI Comparison
SGLY vs PALI Comparison
Compare SGLY & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- PALI
- Stock Information
- Founded
- SGLY 2001
- PALI 1996
- Country
- SGLY United States
- PALI United States
- Employees
- SGLY N/A
- PALI N/A
- Industry
- SGLY
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGLY
- PALI Health Care
- Exchange
- SGLY Nasdaq
- PALI Nasdaq
- Market Cap
- SGLY 4.4M
- PALI 3.7M
- IPO Year
- SGLY 2008
- PALI N/A
- Fundamental
- Price
- SGLY $1.05
- PALI $1.24
- Analyst Decision
- SGLY
- PALI Strong Buy
- Analyst Count
- SGLY 0
- PALI 2
- Target Price
- SGLY N/A
- PALI $12.00
- AVG Volume (30 Days)
- SGLY 42.6K
- PALI 972.6K
- Earning Date
- SGLY 08-26-2025
- PALI 08-11-2025
- Dividend Yield
- SGLY N/A
- PALI N/A
- EPS Growth
- SGLY N/A
- PALI N/A
- EPS
- SGLY N/A
- PALI N/A
- Revenue
- SGLY $2,172,036.00
- PALI N/A
- Revenue This Year
- SGLY N/A
- PALI N/A
- Revenue Next Year
- SGLY N/A
- PALI N/A
- P/E Ratio
- SGLY N/A
- PALI N/A
- Revenue Growth
- SGLY N/A
- PALI N/A
- 52 Week Low
- SGLY $0.54
- PALI $0.60
- 52 Week High
- SGLY $7.65
- PALI $4.65
- Technical
- Relative Strength Index (RSI)
- SGLY 51.17
- PALI 73.32
- Support Level
- SGLY $0.99
- PALI $0.72
- Resistance Level
- SGLY $1.14
- PALI $1.36
- Average True Range (ATR)
- SGLY 0.05
- PALI 0.12
- MACD
- SGLY 0.00
- PALI 0.05
- Stochastic Oscillator
- SGLY 57.14
- PALI 76.47
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.